• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C3 肾小球病组织学评分指数的验证。

Validation of a Histologic Scoring Index for C3 Glomerulopathy.

机构信息

Instituto de Investigación Hospital 12 de octubre (i+12), Madrid, Spain; Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.

Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.

出版信息

Am J Kidney Dis. 2021 May;77(5):684-695.e1. doi: 10.1053/j.ajkd.2020.11.011. Epub 2020 Dec 22.

DOI:10.1053/j.ajkd.2020.11.011
PMID:33359150
Abstract

RATIONALE & OBJECTIVE: A previous study that evaluated associations of kidney biopsy findings with disease progression in patients with C3 glomerulopathy (C3G) proposed a prognostic histologic index (C3G-HI) that has not yet been validated. Our objective was to validate the performance of the C3G-HI in a new patient population.

STUDY DESIGN

Multicenter, retrospective cohort study.

SETTING & PARTICIPANTS: 111 patients fulfilling diagnostic criteria of C3G between January 1995 and December 2019, from 33 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases (GLOSEN).

PREDICTORS

Demographic, clinical parameters, C3G-HI total activity score, and the C3G-HI total chronicity score.

OUTCOME

Time to kidney failure.

ANALYTICAL APPROACH

Intraclass correlation coefficients and κ statistic were used to summarize inter-rater reproducibility for assessment of histopathology in kidney biopsies. The nonlinear relationships of risk of kidney failure with the total activity score and total chronicity score were modeled using Cox proportional hazards analysis that incorporated cubic splines.

RESULTS

The study group included 93 patients with C3 glomerulonephritis and 18 with dense-deposit disease. Participants had an overall meanage of 35±22 (SD) years. Forty-eight patients (43%) developed kidney failure after a mean follow-up of 65±27 months. The overall inter-rater reproducibility was very good for the total activity score (intraclass correlation coefficient [ICC]=0.63) and excellent for total chronicity score (ICC=0.89). Baseline estimated glomerular filtration rate (eGFR), 24-hour proteinuria, and treatment with immunosuppression were the main determinants of kidney failure in a model with only clinical variables. Only tubular atrophy and interstitial fibrosis were identified as predictors in a model with histological variables. When the total activity score and total chronicity score were added to the model, only the latter was identified as an independent predictor of kidney failure.

LIMITATIONS

Only a subset of the kidney biopsies was centrally reviewed. Residual confounding.

CONCLUSIONS

We validated the performance of C3G-HI as a predictor of kidney failure in patients with C3G. The total chronicity score was the principal histologic correlate of kidney failure.

摘要

背景与目的

先前的研究评估了 C3 肾小球病(C3G)患者肾活检结果与疾病进展的相关性,提出了一种尚未得到验证的预后组织学指数(C3G-HI)。我们的目的是在新的患者人群中验证 C3G-HI 的性能。

研究设计

多中心回顾性队列研究。

研究场所和参与者

1995 年 1 月至 2019 年 12 月期间,33 个隶属于西班牙肾小球疾病研究组(GLOSEN)的肾病科共有 111 名符合 C3G 诊断标准的患者。

预测指标

人口统计学、临床参数、C3G-HI 总活动评分和 C3G-HI 总慢性评分。

研究结果

终点事件为肾功能衰竭。

分析方法

采用组内相关系数和κ统计量来总结肾脏活检组织病理学评估的观察者间重复性。采用 Cox 比例风险分析来建立肾功能衰竭风险与总活动评分和总慢性评分之间的非线性关系,该分析采用了三次样条。

研究结果

研究组包括 93 例 C3 肾小球肾炎患者和 18 例致密物沉积病患者。参与者的平均年龄为 35±22(SD)岁。平均随访 65±27 个月后,48 例(43%)患者发生肾功能衰竭。总活动评分的观察者间总体重复性非常好(组内相关系数[ICC]=0.63),总慢性评分的观察者间总体重复性极好(ICC=0.89)。在仅包含临床变量的模型中,基线估计肾小球滤过率(eGFR)、24 小时蛋白尿和免疫抑制治疗是肾功能衰竭的主要决定因素。在包含组织学变量的模型中,仅发现肾小管萎缩和间质纤维化是预测因素。当总活动评分和总慢性评分被添加到模型中时,只有后者被确定为肾功能衰竭的独立预测因素。

局限性

仅对部分肾脏活检进行了中心审查。存在残余混杂因素。

结论

我们验证了 C3G-HI 作为 C3G 患者肾功能衰竭预测因子的性能。总慢性评分是肾功能衰竭的主要组织学相关因素。

相似文献

1
Validation of a Histologic Scoring Index for C3 Glomerulopathy.C3 肾小球病组织学评分指数的验证。
Am J Kidney Dis. 2021 May;77(5):684-695.e1. doi: 10.1053/j.ajkd.2020.11.011. Epub 2020 Dec 22.
2
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.在一项美国大型 C3 肾小球病患者队列中,C3 肾小球肾炎和致密物沉积病具有相似的疾病进程。
Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022. Epub 2018 Jan 6.
3
C3 glomerulopathy: clinicopathologic features and predictors of outcome.C3肾小球病:临床病理特征及预后预测因素
Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513. Epub 2013 Oct 31.
4
Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.日本儿童免疫复合物性膜增生性肾小球肾炎和 C3 肾小球病的临床特征和转归。
Pediatr Nephrol. 2024 Sep;39(9):2679-2689. doi: 10.1007/s00467-024-06377-7. Epub 2024 Apr 25.
5
C3 glomerulonephritis with a severe crescentic phenotype.C3 肾小球肾炎伴严重细胞性新月体表型。
Pediatr Nephrol. 2017 Sep;32(9):1625-1633. doi: 10.1007/s00467-017-3702-8. Epub 2017 Jun 7.
6
Clinicopathological Significance and Renal Outcomes of Light Microscopic Patterns in Complement Component 3 Glomerulopathy.补体成分 3 肾小球病的光镜模式的临床病理意义及肾脏结局。
Nephron. 2020;144(5):228-235. doi: 10.1159/000506290. Epub 2020 Mar 10.
7
Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis.C3 肾小球病和特发性免疫球蛋白相关膜增生性肾小球肾炎的组织学参数与预后的相关性。
Clin J Am Soc Nephrol. 2022 Jul;17(7):994-1007. doi: 10.2215/CJN.16801221.
8
Clinicopathological features of C3 glomerulopathy in children: a single-center experience.儿童 C3 肾小球病的临床病理特征:单中心经验。
Pediatr Nephrol. 2020 Jan;35(1):153-162. doi: 10.1007/s00467-019-04388-3. Epub 2019 Oct 30.
9
C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.与单克隆丙种球蛋白血症相关的 C3 肾小球病:慢性组织学病变的影响和克隆靶向治疗的有益效果。
Nephrol Dial Transplant. 2022 Oct 19;37(11):2128-2137. doi: 10.1093/ndt/gfab302.
10
Defining the complement biomarker profile of C3 glomerulopathy.定义C3肾小球病的补体生物标志物谱。
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1876-82. doi: 10.2215/CJN.01820214. Epub 2014 Oct 23.

引用本文的文献

1
C3 glomerulopathy post kidney transplantation: A single center experience.肾移植后C3肾小球病:单中心经验
World J Transplant. 2025 Jun 18;15(2):101517. doi: 10.5500/wjt.v15.i2.101517.
2
Successful Management of C3 Glomerulopathy Recurrence Post-Kidney Transplantation with Iptacopan: A Case Report.依他库帕成功治疗肾移植后C3肾小球病复发:一例报告
Int J Mol Sci. 2025 May 24;26(11):5053. doi: 10.3390/ijms26115053.
3
Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
免疫复合物型膜增生性肾小球肾炎和C3肾小球病中蛋白尿与纵向预后的比较分析
Kidney Int Rep. 2025 Jan 18;10(4):1223-1236. doi: 10.1016/j.ekir.2025.01.024. eCollection 2025 Apr.
4
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.培克昔单抗治疗复发性补体3肾小球病或原发性免疫复合物膜增生性肾小球肾炎肾移植受者的疗效和安全性
Kidney Int Rep. 2024 Oct 10;10(1):87-98. doi: 10.1016/j.ekir.2024.09.030. eCollection 2025 Jan.
5
Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: a registry analysis.C3肾小球病组织学慢性评分的预后因素及验证:一项注册研究分析
Clin Kidney J. 2024 Mar 20;17(8):sfae077. doi: 10.1093/ckj/sfae077. eCollection 2024 Aug.
6
C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation.移植后 2 年内连续活检发现 C3 肾小球病在肾移植后早期复发。
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1005-1015. doi: 10.2215/CJN.0000000000000474. Epub 2024 Jun 7.
7
Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.儿童和青少年 C3 肾小球病或免疫复合物性膜增生性肾小球肾炎患者的肾移植:CERTAIN 研究网络中的真实世界研究。
Pediatr Nephrol. 2024 Dec;39(12):3569-3580. doi: 10.1007/s00467-024-06476-5. Epub 2024 Aug 7.
8
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.开发C3肾小球病的治疗方法:肾脏健康倡议C3肾小球病试验终点工作组报告
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1201-1208. doi: 10.2215/CJN.0000000000000505. Epub 2024 Jun 3.
9
Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.补体终末途径激活与 C3 肾小球病的肾内免疫反应
J Am Soc Nephrol. 2024 Aug 1;35(8):1034-1044. doi: 10.1681/ASN.0000000000000373. Epub 2024 May 6.
10
C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.C3肾小球病:致密物沉积病和C3肾小球肾炎。
Front Med (Lausanne). 2023 Nov 24;10:1289812. doi: 10.3389/fmed.2023.1289812. eCollection 2023.